Health TrialsbyHealthPanel

HR+ / HER2- Advanced Breast Cancer

1

Review clinical trials related to HR+ / HER2- Advanced Breast Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

This study is a prospective, single-arm, multicenter phase II clinical trial. The study plans to enroll 40 patients with HR+/HER2- advanced breast cancer to explore the efficacy and safety of patients receiving olmesartan, dalpiciclib and aromatase inhibitor treatment.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUpdated: Sep 9, 2026Locations: 1
Eligibility criteria

Women aged 18 to 75 years, either pre-menopausal/post-menopausal or post-menopau... [+9]

Any evidence of severe or uncontrollable systemic diseases, including active ble... [+10]

Read more